指南与共识造血干细胞移植与细胞治疗贫血与红细胞疾病

储存前白细胞去除后减少辐照血制品指征:英国血液学学会指南解读

Guideline development for prevention of transfusion-associated graft-versus-host disease: reduction of indications for irradiated blood components after prestorage leukodepletion of blood components.
指南 / 共识 · Br J Haematol · 2021-09-06

该指南由荷兰输血指南修订工作组制定,评估储存前白细胞去除后是否仍需辐照血制品预防输血相关移植物抗宿主病(TA-GVHD)。检索发现1998至2013年6例疑似病例,其中4例未按已识别指征使用辐照血。指南保留了基于HLA相似性和宫内输血的指征,并定义了长期深度T细胞抑制相关指征的持续时间(治疗结束后6或12个月)。

要点

  • 储存前白细胞去除不能完全替代辐照预防TA-GVHD。
  • 保留HLA相似性和宫内输血相关辐照指征。
  • 长期深度T细胞抑制者需在治疗结束后6或12个月继续辐照。

核心结论

  • 储存前白细胞去除后仍需对特定高风险患者辐照血制品以预防TA-GVHD。

研究设计与样本

  • 指南制定机构为荷兰输血指南修订工作组,方法包括检索已发表病例和联系血液警戒系统。

主要发现

  • 发现6例疑似TA-GVHD病例,发生于1998至2013年,其中4例患者接受了未辐照血制品尽管存在辐照指征。

关键数值与推荐

  • 保留与供受体HLA相似性相关的辐照指征。
  • 保留与宫内输血相关的辐照指征。
  • 长期深度T细胞抑制相关指征定义为治疗结束后6或12个月(如自体或异基因造血干细胞移植)。
  • 强调继续警惕TA-GVHD并报告错误的未辐照输注。

临床怎么用

  • 对HLA相似性供者、宫内输血及长期深度T细胞抑制患者(如移植后6或12个月内)仍应使用辐照血制品。
  • 临床需持续监测TA-GVHD并及时报告未辐照输注错误。

局限性

  • 发现的疑似病例数量有限(6例),且部分病例未遵守已有指征。
  • 数据来自部分提供信息的国家,可能不全面。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare, commonly fatal complication of transfusion preventable by irradiation of blood units. The revision of the Dutch transfusion guideline addressed the question whether irradiation is still necessary if blood components are prestorage leukodepleted. We searched for published cases of TA-GVHD following transfusion of prestorage leukodepleted blood and through contacting haemovigilance systems. Six presumed cases were found, dating from 1998 to 2013. Four out of six patients had received one or more non-irradiated units despite recognised indications for irradiated blood components. In the countries providing information, over 50 million prestorage leukodepleted, non-irradiated, non-pathogen-reduced cellular components were transfused in a 10-year period. Potential benefits of lifting indications for irradiation were considered. These include reduced irradiation costs (€ 1.5 million annually in the Netherlands) and less donor exposure for neonates. Findings were presented in an invitational expert meeting. Recommendations linked to human leukocyte antigen similarity between donor and recipient or intra-uterine transfusion were left unchanged. Indications linked to long-lasting deep T-cell suppression were defined with durations of 6 or 12 months after end of treatment (e.g. autologous or allogeneic stem cell transplantation). Need for continued alertness to TA-GVHD and haemovigilance reporting of erroneous non-irradiated transfusions was emphasised.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wiersum-Osselton JC, Slomp J, Frederik Falkenburg JH, et al. Guideline development for prevention of transfusion-associated graft-versus-host disease: reduction of indications for irradiated blood components after prestorage leukodepletion of blood components. Br J Haematol. 2021. PMID: 34490619. doi:10.1111/bjh.17822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。